Could a common supplement help rare lung disease?

NCT ID NCT05593588

First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether the supplement fisetin can improve lung disease in people with common variable immunodeficiency (CVID). Twenty participants will receive either fisetin or a placebo on four days over a month. The study measures changes in immune cells and lung function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Fisetin (a plant-based supplement)

What this could lead to

If it works, this could point toward a new treatment for lung scarring in people with CVID.

What could go wrong

This is a small early-phase trial with only 20 participants, so results may not apply widely. Fisetin is a supplement and may not be strong enough to change the disease course.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMON VARIABLE IMMUNODEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

common variable immunodeficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States